Maker of the iLet Bionic Pancreas, an automated insulin-delivery system for people with type 1 diabetes.
Maker of the iLet Bionic Pancreas, an automated insulin-delivery system for people with type 1 diabetes.
Sells the iLet device and then earns again and again from the disposable infusion sets and insulin cartridges patients must replace, billed largely through insurance. Distribution runs through pharmacies and medical-supply distributors, which makes insurer coverage decisions as important as sales calls.
In one line: A newer, algorithm-driven rival to Insulet's Omnipod and Tandem's t:slim.
Moat: narrow (IP / patents, process know-how). Proprietary dosing algorithm requires only body weight (no carb counting), differentiating from rival AID systems.
Headquarters: Irvine, California · Founded: 2013 · Employees: 423
Size Beta Bionics (BBNX) is a United States Health Care company (Medical Specialties) with a market value of $779M, the 2387th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.33 on 18 Nov 2026.
Performance Over six months the shares gained 41.7%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 43.7% over the last twelve months (peer median +10.2%); the operating margin is -72.8% (peer median 12.8%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.1× (7th most expensive of 21).
Capital Return on invested capital runs 63.7 points below its cost of capital (20.0% WACC).
Backlog Backlog (remaining performance obligations) was $2.00M at 30 Sep 2026, up 54% on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 9.2% of the free float (30 Oct 2026).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $127M | $100M | $65.1M | $12.0M | $179,000 |
| Revenue growth | — | +54% | +443% | +6,601% | — |
| Gross profit | $74.6M | $55.5M | $35.9M | $6.31M | -$1.91M |
| EBITDA | -$88.6M | -$68.8M | -$43.0M | -$33.8M | -$63.8M |
| Net income | -$83.1M | -$73.2M | -$54.8M | -$44.1M | -$64.8M |
| Free cash flow | -$66.0M | -$56.2M | -$51.7M | -$32.8M | -$61.0M |
| Capital expenditure | $6.59M | $5.30M | $3.40M | $402,000 | $772,000 |
| Total debt | $6.10M | $7.30M | $7.25M | $4.22M | $4.13M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beta Bionics BBNX | $779M | +42% | +44% | -73% | 4.3× | n/a |
| Insulet PODD | $9.71B | -11% | +26% | 18% | 3.2× | 10.6% |
| Tandem Diabetes Care TNDM | $1.19B | +13% | +7% | -2% | 1.4× | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 4.0× | 9.1% |
| Dexcom DXCM | $30.8B | +16% | +13% | 24% | 6.0× | 19.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BBNX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.2% | -6.7% | 4th lowest of 21 |
| 6-month return | +41.7% | -17.5% | 4th highest of 21 |
| Distance from 52-week high | -56.2% | -39.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +43.7% | +10.2% | 2nd highest of 21 |
| Operating margin | -72.8% | 12.8% | 2nd lowest of 21 |
| EV / Sales | 4.3× | 3.1× | 7th most expensive of 21 |
| ROIC minus cost of capital | -63.7 pp | -0.3 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | 7.7× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 1.2× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 3.6× | 3.8% | +105.8% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 2.3× | 7.9% | -10.2% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 7.8× | 27.9% | +9.9% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | 1.5× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 2.8× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 1.7× | 20.3% | -0.2% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 0.6× | -10.8% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | 4.5× | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 1.8× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 5.8× | 17.1% | +24.2% |
Beta Bionics reported $2.00M of remaining performance obligations at 30 Sep 2026, up 54% from a year earlier and up 5% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.